Emergent BioSolutions (EBS) investor relations material

Executive summary

• Q2 2026 revenues reached $234.3M, up 66% year-over-year, driven by accelerated MCM deliveries and strong US government partnerships, while Commercial Product sales declined due to lower NARCAN® volumes and pricing.

• Net loss for Q2 2026 was $180.2M, primarily due to a $191.3M non-cash impairment charge related to the NARCAN® asset group.

• Organizational restructuring is underway, targeting $40M in annualized savings through workforce reductions, lab closures, and asset sales.

• Continued execution of a multi-year transformation plan focused on operational efficiency, international MCM expansion, product innovation, and unified R&D and business development.

• Strategic partnerships and contract wins, including new deals for ACAM2000®, BAT®, and manufacturing collaborations, were secured.

Financial highlights

• Q2 2026 revenue was $234M, up from $141M in Q2 2025; year-to-date revenue reached $390.4M, up 8% year-over-year.

• Q2 adjusted EBITDA was $97M (41% margin), up from $33M (23% margin) in Q2 2025; year-to-date adjusted EBITDA was $132M (34% margin), up from $112M (31% margin) year-over-year.

• Q2 2026 net loss was $180.2M, primarily due to the $191.3M NARCAN® impairment; adjusted net income was $30.9M.

• Adjusted gross margin improved to 58% in Q2 and 56% year-to-date; Q2 gross margin was 50%, up from 36% in Q2 2025.

• Ended Q2 with $140M in cash and $190M in total liquidity; gross debt was $590M, net debt $450M, and net leverage ratio stable at 1.9x trailing 12-month adjusted EBITDA.

Outlook and guidance

• Full-year 2026 revenue guidance revised to $645–$675M (down from $720–$760M), reflecting lower expected commercial revenue due to increased naloxone competition and pricing pressure.

• GAAP net loss guidance now $(245)–$(225)M, including non-cash impairment and restructuring costs; adjusted net income guidance $10–$30M; adjusted EBITDA guidance $130–$150M; adjusted gross margin guidance 42–44%.

• Q3 2026 revenue expected between $110–$130M, reflecting step-down after accelerated MCM deliveries and ongoing naloxone market pressure.

• Commercial revenues projected to decline 20–25% YoY; MCM revenues expected to be flat or slightly down with increased international contribution.

• Management expects continued variability in quarterly results due to the timing of government contracts and product deliveries.